See more : Unibail-Rodamco-Westfield SE (UNBLF) Income Statement Analysis – Financial Results
Complete financial analysis of Mereo BioPharma Group plc (MREO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mereo BioPharma Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
- SRS Holdings Co.,Ltd. (8163.T) Income Statement Analysis – Financial Results
- Credit Bank of Moscow (public joint-stock company) (CBOM.ME) Income Statement Analysis – Financial Results
- Labrador Gold Corp. (NKOSF) Income Statement Analysis – Financial Results
- Polaris Inc. (0KJQ.L) Income Statement Analysis – Financial Results
- Wayi International Digital Entertainment Co., Ltd. (3086.TWO) Income Statement Analysis – Financial Results
Mereo BioPharma Group plc (MREO)
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 1.51M | 36.46M | 393.00K | -122.00K | 0.00 | -3.29M | 0.00 |
| Cost of Revenue | 2.57M | 936.00K | 17.91M | 16.35M | 23.61M | 22.70M | 34.61M | 24.56M |
| Gross Profit | 7.43M | 571.00K | 18.56M | -15.95M | -23.73M | -22.70M | -37.89M | -24.56M |
| Gross Profit Ratio | 74.26% | 37.89% | 50.89% | -4,059.54% | 19,450.82% | 0.00% | 1,153.38% | 0.00% |
| Research & Development | 17.42M | 24.96M | 23.56M | -16.35M | -23.61M | 22.70M | 34.61M | 24.56M |
| General & Administrative | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Other Expenses | 0.00 | 811.00K | 0.00 | 0.00 | 0.00 | 0.00 | -293.33K | 0.00 |
| Operating Expenses | 35.84M | 44.51M | 39.49M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Cost & Expenses | 38.42M | 43.57M | 57.40M | 37.57M | 39.52M | 35.21M | 45.30M | 36.18M |
| Interest Income | 2.13M | 696.00K | 1.00K | 44.00K | 377.00K | 306.83K | 826.86K | 195.14K |
| Interest Expense | 2.88M | 3.36M | 4.00M | 6.38M | 3.50M | 2.36M | 1.09M | 179.77K |
| Depreciation & Amortization | 1.06M | 1.51M | 866.47K | 44.00K | 1.95M | 37.80K | 36.08K | 32.94K |
| EBITDA | -26.06M | -42.06M | -5.00M | -37.53M | -37.56M | -34.86M | -44.44M | -38.41M |
| EBITDA Ratio | -260.56% | -2,791.11% | -55.71% | -9,548.35% | 30,789.34% | 0.00% | 1,352.72% | 0.00% |
| Operating Income | -28.42M | -43.57M | -20.94M | -37.57M | -39.52M | -35.21M | -45.30M | -36.18M |
| Operating Income Ratio | -284.16% | -2,891.11% | -57.42% | -9,559.54% | 32,390.98% | 0.00% | 1,378.99% | 0.00% |
| Total Other Income/Expenses | -1.58M | 7.48M | 40.16M | -129.27M | -1.60M | -2.10M | -1.65M | 2.46M |
| Income Before Tax | -30.00M | -36.09M | 14.24M | -166.45M | -41.12M | -37.31M | -46.95M | -33.72M |
| Income Before Tax Ratio | -299.98% | -2,395.02% | 39.05% | -42,353.69% | 33,703.28% | 0.00% | 1,429.13% | 0.00% |
| Income Tax Expense | -532.00K | -1.90M | 1.52M | -2.82M | -6.27M | -5.28M | -8.15M | -5.33M |
| Net Income | -29.47M | -34.20M | 12.73M | -163.63M | -34.84M | -32.03M | -38.80M | -28.39M |
| Net Income Ratio | -294.66% | -2,269.14% | 34.90% | -41,635.62% | 28,560.66% | 0.00% | 1,180.99% | 0.00% |
| EPS | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| EPS Diluted | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| Weighted Avg Shares Out | 659.45M | 603.20M | 527.82M | 337.72M | 89.34M | 71.14M | 69.01M | 44.79M |
| Weighted Avg Shares Out (Dil) | 659.45M | 603.20M | 555.28M | 338.95M | 89.42M | 71.14M | 69.01M | 44.79M |
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Verde Reports up to 13,944 ppm TREO 5,222 ppm MREO and 213 ppm DyTb
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Verde's assays of over 1,500m of drilling find rare earths up to 12,487 ppm TREO and 3,357 ppm MREO
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Equities Analysts Offer Predictions for Mereo BioPharma Group plc’s Q2 2024 Earnings (NASDAQ:MREO)
Source: https://incomestatements.info
Category: Stock Reports